Abstract

Ranibizumab (Lucentis) vs Aflibercept (Eyelea) for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in rural clinical practice

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call